{
    "id": "15648e21-08f9-4f3c-a7ab-9d2033330576",
    "indications": {
        "text": "valacyclovir tablet deoxynucleoside analogue dna polymerase inhibitor indicated : adult patients ( 1.1 ) \u2022 cold sores ( herpes labialis ) \u2022 genital herpes \u2022 treatment immunocompetent patients ( initial recurrent episode ) \u2022 suppression immunocompetent hiv-1-infected patients \u2022 reduction transmission \u2022 herpes zoster pediatric patients ( 1.2 ) \u2022 cold sores ( herpes labialis ) \u2022 chickenpox limitations ( 1.3 ) efficacy safety valacyclovir tablets established immunocompromised patients suppression genital herpes hiv-1-infected patients .",
        "doid_entities": [
            {
                "text": "cold (DOID:3083)",
                "doid_id": "http://purl.obolibrary.org/obo/DOID_3083"
            },
            {
                "text": "genital herpes (DOID:8704)",
                "doid_id": "http://purl.obolibrary.org/obo/DOID_8704"
            },
            {
                "text": "herpes zoster (DOID:8536)",
                "doid_id": "http://purl.obolibrary.org/obo/DOID_8536"
            },
            {
                "text": "chickenpox (DOID:8659)",
                "doid_id": "http://purl.obolibrary.org/obo/DOID_8659"
            }
        ],
        "orphanet_entities": []
    },
    "contraindications": {
        "text": "\u2022 valacyclovir tablets may given without regard meals . \u2022 valacyclovir oral suspension ( 25 mg/ml 50 mg/ml ) may prepared extemporaneously 500-mg valacyclovir tablets pediatric patients solid form appropriate [ ( 2.3 ) ] .",
        "doid_entities": [],
        "orphanet_entities": []
    },
    "warningsAndPrecautions": "product : 50090-2510 product : 50090-2575 ndc : 50090-2575-0 15 tablet , film coated bottle ndc : 50090-2575-1 21 tablet , film coated bottle ndc : 50090-2575-2 30 tablet , film coated bottle ndc : 50090-2575-3 90 tablet , film coated bottle",
    "adverseReactions": "valacyclovir tablets contraindicated patients demonstrated clinically significant hypersensitivity reaction ( e.g . , anaphylaxis ) valacyclovir , acyclovir , component formulation [ ( 6.3 ) ] .",
    "ingredients": [
        {
            "name": "CROSPOVIDONE (120 .MU.M)",
            "code": "68401960MK"
        },
        {
            "name": "HYDROXYPROPYL METHYLCELLULOSE",
            "code": "3NXW29V3WO",
            "chebi_id": "http://purl.obolibrary.org/obo/CHEBI_30618"
        },
        {
            "name": "MAGNESIUM STEARATE",
            "code": "70097M6I30",
            "drugbank_id": "https://go.drugbank.com/drugs/DB14077"
        },
        {
            "name": "CELLULOSE, MICROCRYSTALLINE",
            "code": "OP1R32D61U"
        },
        {
            "name": "PEG-20 SORBITAN OLEATE",
            "code": "6OZP39ZG8H",
            "chebi_id": "http://purl.obolibrary.org/obo/CHEBI_172670"
        },
        {
            "name": "POVIDONE, UNSPECIFIED",
            "code": "FZ989GH94E"
        },
        {
            "name": "TITANIUM DIOXIDE",
            "code": "15FIX9V2JP",
            "chebi_id": "http://purl.obolibrary.org/obo/CHEBI_32234"
        },
        {
            "name": "FD&C BLUE NO. 2",
            "code": "L06K8R7DQK"
        },
        {
            "name": "POLYETHYLENE GLYCOL, UNSPECIFIED",
            "code": "3WJQ0SDW1A",
            "chebi_id": "http://purl.obolibrary.org/obo/CHEBI_13643"
        },
        {
            "name": "VALACYCLOVIR HYDROCHLORIDE",
            "code": "G447S0T1VC",
            "chebi_id": "http://purl.obolibrary.org/obo/CHEBI_9919"
        }
    ],
    "organization": "A-S Medication Solutions",
    "name": "Valacyclovir",
    "effectiveTime": "20250506",
    "indications_original": "Valacyclovir tablet is a deoxynucleoside analogue DNA polymerase inhibitor indicated for: Adult Patients ( 1.1 ) \u2022 Cold Sores (Herpes Labialis) \u2022 Genital Herpes \u2022 Treatment in immunocompetent patients (initial or recurrent episode) \u2022 Suppression in immunocompetent or HIV-1-infected patients \u2022 Reduction of transmission \u2022 Herpes Zoster Pediatric Patients ( 1.2 ) \u2022 Cold Sores (Herpes Labialis) \u2022 Chickenpox Limitations of Use ( 1.3 ) The efficacy and safety of valacyclovir tablets have not been established in immunocompromised patients other than for the suppression of genital herpes in HIV-1-infected patients.",
    "contraindications_original": "\u2022 Valacyclovir tablets may be given without regard to meals. \n    \u2022 Valacyclovir oral suspension (25 mg/mL or 50 mg/mL) may be prepared extemporaneously from 500-mg valacyclovir tablets for use in pediatric patients for whom a solid dosage form is not appropriate\n \n  [see Dosage and Administration (\n  \n   2.3)].",
    "warningsAndPrecautions_original": "Product:    50090-2510\n                  Product:    50090-2575\n                  NDC:    50090-2575-0   15 TABLET, FILM COATED in a BOTTLE\n                  NDC:    50090-2575-1   21 TABLET, FILM COATED in a BOTTLE\n                  NDC:    50090-2575-2   30 TABLET, FILM COATED in a BOTTLE\n                  NDC:    50090-2575-3   90 TABLET, FILM COATED in a BOTTLE",
    "adverseReactions_original": "Valacyclovir tablets are contraindicated in patients who have had a demonstrated clinically significant hypersensitivity reaction (e.g., anaphylaxis) to valacyclovir, acyclovir, or any component of the formulation\n \n  [see Adverse Reactions (\n  \n   6.3)].",
    "drug": [
        {
            "name": "Valacyclovir",
            "chebi_id": "http://purl.obolibrary.org/obo/CHEBI_35854"
        }
    ]
}